• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过感染野生型或变异病毒的K18-hACE2小鼠血清鉴定的新冠病毒刺突蛋白的免疫显性线性B细胞表位

Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses.

作者信息

Levy Yinon, Alcalay Ron, Zvi Anat, Makdasi Efi, Peretz Eldar, Noy-Porat Tal, Chitlaru Theodor, Mandelboim Michal, Mazor Ohad, Rosenfeld Ronit

机构信息

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.

The Central Virology Laboratory, Israel Ministry of Health, Tel Hashomer, Ramat Gan 5266202, Israel.

出版信息

Vaccines (Basel). 2022 Feb 7;10(2):251. doi: 10.3390/vaccines10020251.

DOI:10.3390/vaccines10020251
PMID:35214711
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8875268/
Abstract

SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile of SARS-CoV-2 proteins in general, and that of the spike protein in particular, may contribute to the development of sensitive diagnostic tools and identification of vaccine` candidate targets. In the current study, the anti-viral antibody response in transgenic K18-hACE-2 mice was examined by implementing an immunodominant epitope mapping approach of the SARS-CoV-2 spike. Serum samples for probing an epitope array covering the entire spike protein were collected from mice following infection with the original SARS-CoV-2 strain as well as the B.1.1.7 Alpha and B.1.351 Beta genetic variants of concern. The analysis resulted in distinction of six linear epitopes common to the humoral response against all virus variants inspected at a frequency of more than 20% of the serum samples. Finally, the universality of the response was probed by cross-protective in vitro experiments using plaque-reducing neutralization tests. The data presented here has important implications for prediction of the efficacy of immune countermeasures against emerging SARS-CoV-2 variants.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)表面刺突蛋白介导病毒进入宿主细胞,是2019冠状病毒病(COVID-19)疫苗以及暴露后免疫治疗的主要免疫靶点。确定SARS-CoV-2蛋白,尤其是刺突蛋白的高免疫原性B细胞表位谱,可能有助于开发灵敏的诊断工具并识别疫苗候选靶点。在本研究中,通过对SARS-CoV-2刺突蛋白实施免疫显性表位定位方法,检测了转基因K18-hACE-2小鼠的抗病毒抗体反应。在用原始SARS-CoV-2毒株以及值得关注的B.1.1.7 Alpha和B.1.351 Beta基因变体感染小鼠后,收集用于探测覆盖整个刺突蛋白的表位阵列的血清样本。分析结果区分出了六种线性表位,这些表位在针对所有检测病毒变体的体液反应中常见,在血清样本中的出现频率超过20%。最后,通过使用蚀斑减少中和试验的交叉保护性体外实验探究了反应的普遍性。本文提供的数据对于预测针对新出现的SARS-CoV-2变体的免疫对策的效果具有重要意义。

相似文献

1
Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses.通过感染野生型或变异病毒的K18-hACE2小鼠血清鉴定的新冠病毒刺突蛋白的免疫显性线性B细胞表位
Vaccines (Basel). 2022 Feb 7;10(2):251. doi: 10.3390/vaccines10020251.
2
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体,提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
3
Host immune responses associated with SARS-CoV-2 Omicron infection result in protection or pathology during reinfection depending on mouse genetic background.与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变异株感染相关的宿主免疫反应,在再次感染期间会根据小鼠的遗传背景导致保护作用或病理变化。
Res Sq. 2023 Nov 29:rs.3.rs-3637405. doi: 10.21203/rs.3.rs-3637405/v1.
4
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
5
SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.SARS-CoV-2 引起人类 ACE2 基因敲入小鼠肺部感染但不引起严重疾病。
J Virol. 2022 Jan 12;96(1):e0151121. doi: 10.1128/JVI.01511-21. Epub 2021 Oct 20.
6
VSV-ΔG-Spike Candidate Vaccine Induces Protective Immunity and Protects K18-hACE2 Mice against SARS-CoV-2 Variants.VSV-ΔG-Spike 候选疫苗诱导保护性免疫,并保护 K18-hACE2 小鼠免受 SARS-CoV-2 变体的侵害。
Viruses. 2023 Jun 13;15(6):1364. doi: 10.3390/v15061364.
7
Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach.揭示 SARS-CoV-2 未注释的 ORF 抗原中存在的有效表位,为基于表位的多价疫苗设计提供免疫信息学方法。
Front Immunol. 2021 Aug 23;12:692937. doi: 10.3389/fimmu.2021.692937. eCollection 2021.
8
Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.传染性克隆产生的 SARS-CoV-2 可导致感染 K18-Human ACE2 小鼠发生严重肺部疾病。
mBio. 2021 Apr 20;12(2):e00819-21. doi: 10.1128/mBio.00819-21.
9
Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting.通过生物信息学和单克隆抗体靶向技术鉴定针对 SARS-CoV-2 刺突蛋白的中和抗体的 B 细胞表位。
Int J Mol Sci. 2022 Apr 14;23(8):4341. doi: 10.3390/ijms23084341.
10
SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains.SARS-CoV-2 B.1.1.7(阿尔法)和 B.1.351(贝塔)变体在 K18-hACE2 转基因小鼠中引起的发病模式与早期株不同。
Nat Commun. 2021 Nov 12;12(1):6559. doi: 10.1038/s41467-021-26803-w.

引用本文的文献

1
Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19.五年间新冠病毒变异株中刺突蛋白特异性中和抗体的动态变化揭示了可预防重症新冠的保守表位。
Front Immunol. 2025 Feb 18;16:1503954. doi: 10.3389/fimmu.2025.1503954. eCollection 2025.
2
Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2.先前感染季节性冠状病毒并不能保护雄性叙利亚仓鼠免受 SARS-CoV-2 的挑战。
Nat Commun. 2023 Sep 26;14(1):5990. doi: 10.1038/s41467-023-41761-1.

本文引用的文献

1
Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.新型冠状病毒疫苗亚型、疗效和地理分布综述。
Postgrad Med J. 2022 May 1;98(1159):389-394. doi: 10.1136/postgradmedj-2021-140654.
2
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission.N501Y 刺突突变增强了 SARS-CoV-2 的感染和传播。
Nature. 2022 Feb;602(7896):294-299. doi: 10.1038/s41586-021-04245-0. Epub 2021 Nov 24.
3
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
抗 SARS-CoV-2 治疗性人源单克隆抗体对病毒变异体的中和效力保持不变。
Cell Rep. 2021 Sep 7;36(10):109679. doi: 10.1016/j.celrep.2021.109679. Epub 2021 Aug 21.
4
Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern.严重急性呼吸综合征冠状病毒2型高效价静脉注射用人免疫球蛋白的表位多样性及对关注变异株的中和作用
iScience. 2021 Sep 24;24(9):103006. doi: 10.1016/j.isci.2021.103006. Epub 2021 Aug 20.
5
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity.SARS-CoV-2 天然突变对刺突结构、构象和抗原性的影响。
Science. 2021 Aug 6;373(6555). doi: 10.1126/science.abi6226. Epub 2021 Jun 24.
6
SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)突变、疫苗与免疫:关注变异株的影响
Signal Transduct Target Ther. 2021 May 22;6(1):203. doi: 10.1038/s41392-021-00623-2.
7
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model.GC-376对K18 hACE2转基因小鼠模型中SARS-CoV-2病毒感染的疗效。
Sci Rep. 2021 May 5;11(1):9609. doi: 10.1038/s41598-021-89013-w.
8
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白N端结构域的治疗性抗体可保护感染致死剂量病毒的K18人血管紧张素转换酶2(hACE2)小鼠。
iScience. 2021 May 21;24(5):102479. doi: 10.1016/j.isci.2021.102479. Epub 2021 Apr 26.
9
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.SARS-CoV-2 变异株 P.1 对抗体中和的抵抗力增强。
Cell Host Microbe. 2021 May 12;29(5):747-751.e4. doi: 10.1016/j.chom.2021.04.007. Epub 2021 Apr 18.
10
SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients.SARS-CoV-2 全蛋白组分析揭示了 COVID-19 患者中显著的抗原表位特征。
Front Immunol. 2021 Mar 23;12:629185. doi: 10.3389/fimmu.2021.629185. eCollection 2021.